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IMPORTANCE Secondary hyperparathyroidism contributes to extraskeletal calcification and is
associated with all-cause and cardiovascular mortality. Control is suboptimal in themajority of
patients receiving hemodialysis. An intravenously (IV) administered calcimimetic could
improve adherence and reduce adverse gastrointestinal effects.
OBJECTIVE To evaluate the relative efficacy and safety of the IV calcimimetic etelcalcetide
and the oral calcimimetic cinacalcet.
DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind, double-dummy active
clinical trial was conducted comparing IV etelcalcetide vs oral placebo and oral cinacalcet vs
IV placebo in 683 patients receiving hemodialysis with serum parathyroid hormone (PTH)
concentrations higher than 500 pg/mL on active therapy at 164 sites in the United States,
Canada, Europe, Russia, and New Zealand. Patients were enrolled from August 2013 to May
2014, with end of follow-up in January 2015.
INTERVENTIONS Etelcalcetide intravenously and oral placebo (n = 340) or oral cinacalcet and
IV placebo (n = 343) for 26 weeks. The IV study drug was administered 3 times weekly with
hemodialysis; the oral study drug was administered daily.
MAIN OUTCOMES ANDMEASURES The primary efficacy end point was noninferiority of
etelcalcetide at achieving more than a 30% reduction from baseline in mean predialysis PTH
concentrations during weeks 20-27 (noninferiority margin, 12.0%). Secondary end points
included superiority in achieving biochemical end points (>50% and >30% reduction in PTH)
and self-reported nausea or vomiting.
RESULTS Themean (SD) age of the trial participants was 54.7 (14.1) years and 56.2%were
men. Etelcalcetide was noninferior to cinacalcet on the primary end point. The estimated
difference in proportions of patients achieving reduction in PTH concentrations of more than
30% between the 198 of 343 patients (57.7%) randomized to receive cinacalcet and the 232
of 340 patients (68.2%) randomized to receive etelcalcetide was −10.5% (95% CI, −17.5% to
−3.5%, P for noninferiority, <.001; P for superiority, .004). One hundred seventy-eight
patients (52.4%) to randomized etelcalcetide achievedmore than 50% reduction in PTH
concentrations compared with 138 patients (40.2%) randomized to cinacalcet (P = .001;
difference in proportions, 12.2%; 95% CI, 4.7% to 19.5%). Themost common adverse effect
was decreased blood calcium (68.9% vs 59.8%).
CONCLUSIONS AND RELEVANCE Among patients receiving hemodialysis withmoderate to
severe secondary hyperparathyroidism, the use of etelcalcetide was not inferior to cinacalcet
in reducing serum PTH concentrations over 26 weeks; it also met superiority criteria. Further
studies are needed to assess clinical outcomes as well as longer-term efficacy and safety.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT1896232
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S econdaryhyperparathyroidism is an important compli-cationof chronickidneydisease (CKD)andend-stage re-nal disease, particularly among patients receiving di-
alysis. Elevatedserumconcentrationsofparathyroidhormone
(PTH) contribute to bone and cardiovascular disorders (in-
cludingosteitis fibrosa cystica and calcific cardiovascular dis-
ease, broadly referred toasCKD–mineral bonedisorder), along
with myopathy, neuropathy, anemia, and pruritus and have
been independently associatedwith all-cause and cardiovas-
cularmortality.1,2 Current treatmentoptions consist of theoral
administration of intestinal phosphate binders, oral or intra-
venous (IV) calcitriol or active vitaminDanalogs, and the oral
calcimimetic agent cinacalcet.
Etelcalcetide (formerlyAMG416) isasyntheticpeptide that
comprises 7D-amino acids linked to anL-cysteine via a disul-
fide bond and functions as an activator of the calcium sens-
ing receptor. Recently, 2 phase 3 placebo-controlled clinical
trials demonstrated efficacy of etelcalcetide in reducing PTH
(above andbeyond that achievedby conventional therapy) by
30% ormore in 75% of treated patients compared with fewer
than 10% of patients treated with placebo; asymptomatic re-
duced serum calcium was the most common (and expected)
adverse effect.3
Cinacalcet iswidely used in themanagement ofmoderate
to severe secondary hyperparathyroidism in patients under-
goingdialysis,particularly thesizeable fractionofpatientswith
contraindications (eg, hypercalcemia) or refractory to therapy
with calcitriol or active vitamin D analogs.4 Persistent use of
cinacalcet has been limited in clinical practice by a relatively
high frequency of gastrointestinal adverse effects, particu-
larly nausea and vomiting. We undertook the current trial to
compare the relative efficacy and safety of etelcalcetide and
cinacalcet, using a double-blind double-dummy design.
Methods
Study Setting
The trial was conducted at 164 sites in United States, Canada,
Europe, Russia, and New Zealand. The trial was approved by
institutional reviewboards at participating study sites, andall
participants signed informed consent (see trial protocol
Supplement 1, protocol amendment 1 in Supplement 2, pro-
tocol amendment 1 changes inSupplement3, protocol amend-
ment 2 in Supplement 4, protocol amendment 2 changes in
Supplement 5, protocol amend 3 in Supplement 6, protocol
amendment 3 changes in Supplement 7 and statistical analy-
sis plan in Supplement 8).
Participants
Patients receiving thrice weekly maintenance hemodialysis
withmoderate to severe secondaryhyperparathyroidism(pre-
dialysis serumPTH>500pg/mL; to convert to nanogramsper
liter, multiply by 0.1053) on stable doses of calcium supple-
ments or phosphate binders and calcitriol or active vitaminD
analogs with albumin-corrected serum calcium of 8.3 mg/dL
or higher (to convert tomillimoles per liter, multiply by 0.25)
were eligible for randomization. A complete list of inclusion
and exclusion criteria is available in Supplement 9. Race and
ethnicity were obtained to assess generalizability to clinical
practice and were determined by self-report using fixed cat-
egories (white, black or African American, Asian, Native
HawaiianorPacific Islander,American IndianorAlaskaNative,
and other). Eligible patients could not have received cinacal-
cet during the 3months prior to the first screening laboratory
assessments, andtheuseofcommercial cinacalcet therapywas
prohibited during the study.
Study Design
This head-to-head comparison of etelcalcetide and cinacal-
cet was a phase 3, multinational, randomized, active control,
double-blind, double-dummy, dose-titration trial with a
26-week treatment period to compare the therapeutic effi-
cacy and safety of IV etelcalcetide and oral cinacalcet in pa-
tients receiving hemodialysis with moderate to severe sec-
ondary hyperparathyroidism. All patients, regardless of
treatment assignment, received standard care with phos-
phatebinders andcalcitriol or activevitaminDanalogs, aspre-
scribed by the individual investigator.
Procedures
Eligible patients were randomized 1:1 to receive either IV
etelcalcetide and oral placebo or oral cinacalcet and IV pla-
cebo by an interactive voice or web response system. Per-
muted block randomization with a block size of 4 was used,
stratified by region (North America and non-North America)
andscreeningPTH(<900and≥900pg/mL).Patientswhowere
randomized to treatment with IV etelcalcetide and oral pla-
cebo received thriceweekly IVdosesof etelcalcetideat theend
of each hemodialysis session and daily oral doses of placebo
tablets. Patientswhowere randomized to treatmentwith oral
cinacalcet and IVplacebo receiveddaily oral doses of cinacal-
cet tablets, and thrice weekly IV doses of placebo at the end
of each hemodialysis session. The IV study drug was admin-
istered via bolus injection into the venous line of the dialysis
circuit, immediately prior to or during rinse-back after each
hemodialysis session for 26 weeks.
Key Points
Question What is the effect of the intravenous calcimimetic
etelcalcetide compared with the oral calcimimetic cinacalcet on
serum parathyroid hormone (PTH) concentrations in patients
receiving hemodialysis?
Findings In a randomized clinical trial that included 683 adults
receiving hemodialysis with PTH levels higher than 500 pg/mL,
68.2% of patients randomized to receive etelcalcetide
vs 57.7% randomized to receive cinacalcet experiencedmore than
a 30% reduction in mean PTH concentrations over 27 weeks,
a significant difference.
Meaning Etelcalcetide wasmore effective than cinacalcet in
lowering PTH concentrations in patients receiving dialysis with
secondary hyperparathyroidism receiving hemodialysis, but
further research is needed to assess clinical outcomes as well as
longer-term efficacy and safety.
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Dosing
The starting dose of IV etelcalcetide was 5 mg thrice weekly
after hemodialysis and the starting dose of oral cinacalcet
was 30 mg daily. Etelcalcetide (and corresponding IV pla-
cebo) could be titrated in increments of 2.5 mg or 5 mg (dose
range, 2.5-15 mg) and cinacalcet (and corresponding oral pla-
cebo) in increments of 30 mg (dose range, 30-180 mg) at
weeks 5, 9, 13, and 17, with the target serum PTH levels from
100 to 300 pg/mL. Dose titration was managed by an interac-
tive voice or web response system; investigators were
blinded to serum PTH results. Study drug was withheld for 2
consecutive PTH values less than 100 pg/mL, serum calcium
less than 7.5 mg/dL, symptomatic hypocalcemia, or drug-
related adverse events. Serum calcium, albumin, and PTH
levels were monitored every 2 weeks.
Biochemical and Other Determinations
All biochemical data were analyzed in central laboratories.
Parathyroid hormone was analyzed in serum samples using
the Advia Centaur assay (Covance, population reference
range, 14-72 pg/mL). In addition to serum calcium, phos-
phate, and albumin, intact phosphatonin fibroblast growth
factor 23 (FGF23), serum bone-specific alkaline phosphatase,
and collagen type 1 cross-linked C-telopeptide were mea-
sured at baseline and at weeks 12 and 27.
Self-reported Nausea and Vomiting
Patients were instructed to complete an instrument including
(1) a visual analog scale assessing the presence and severity of
nausea and (2) a single question on whether the patient had
vomited that day, each evening using an electronic device.
End Points
The primary efficacy (noninferiority) end point was the pro-
portion of patients with more than 30% reduction from base-
line in mean PTH concentrations during the efficacy assess-
ment phase (weeks 20-27). Key secondary end points
included the proportion of patients with more than a 50%
andmore than a 30% reduction in PTH concentrations (supe-
riority), and the mean weekly days of self-reported nausea
and vomiting over the first 8 weeks. Relative effects on
FGF23, bone-specific alkaline phosphatase, and collagen
type 1 cross-linked C-telopeptide were considered explor-
atory end points. The assessment of all end points was
blinded to allocation group.
Sample Size Determination
A noninferiority margin was determined based on
data from the Evaluation of Cinacalcet Hydrochloride
Therapy to Lower CardioVascular Events (EVOLVE) trial.5 In
the EVOLVE trial, 60% of patients in the cinacalcet group
achieved at least 30% PTH concentrations reduction at
6 months. Assuming that 60% of patients achieve more
than 30% reduction from baseline in mean predialysis
PTH during the efficacy assessment phase, 300 patients
per treatment group would provide 90% power to dem-
onstrate noninferiority, using a margin of 12% for the
upper bound of the 95% 2-sided CI for the treatment dif-
ference (ie, the proportion of cinacalcet-treated patients
minus etelcalcetide-treated patients). For the test of superi-
ority based on a more than 50% reduction in PTH concentra-
tion, 300 patients per treatment group would provide a
90% power to detect a statistically significant difference
between treatment groups, assuming 60% and 45%
response rates in patients randomized to etelcalcetide and
cinacalcet, respectively. These assumptions were based on
data from a phase 2 open-label etelcalcetide study6 and
EVOLVE, respectively.
Statistical Analysis
All data were analyzed according to the intention-to-treat
principle. Where applicable, analyses were adjusted for ran-
domization stratification factors. For the noninferiority
analysis, the Mantel-Haenszel method was applied to com-
pute the 2-sided 95% CI for the difference between the pro-
portion of patients who achieved a more than 30% reduction
from baseline in mean predialysis serum PTH concentrations
during the efficacy assessment phase in the etecalcetide and
cinacalcet groups. The proportion of patients achieving a
reduction in PTH concentrations of more than 50% and
more than 30% during the efficacy assessment phase was
analyzed with the Cochrane-Mantel-Haenszel test. Missing
data were handled as follows: For the primary (noninferior-
ity) analysis, multiple imputation under the noninferiority
null method7 was used if patients had missing PTH data dur-
ing the efficacy assessment phase. Under this imputation
approach, a response rate of 60% was applied to impute
response status in patients in the cinacalcet group with
missing data. A response rate of 48% was applied to impute
response status in patients in the etelcalcetide group with
Figure 1. FlowDiagram of Patients Through the Trial
1006 Patients undergoing hemodialysis with
PTH concentrations ≥500 pg/mL screened 
323 Patients excluded (did not
meet inclusion criterion)a
683 Randomized
340 Randomized to receive
etelcalcetide
338 Received etelcalcetide as
randomized
2 Did not receive etelcalcetide
as randomized
343 Randomized to receive
cinacalcet
341 Received cinacalcet as
randomized
2 Did not receive cinacalcet
as randomized
287 Completed study
53 Discontinued study
31 Withdrew consent
12 Lost to follow-up
10 Died
294 Completed study
49 Discontinued study
32 Withdrew consent
9 Lost to follow-up
6 Died
2 Decision by sponsor
340 Included in the primary analysis 343 Included in the primary analysis
PTH indicates parathyroid hormone.
a Specific reasons were not available.
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missing data. The imputation was performed 5 times to
account for variability introduced by imputation. For the
superiority analyses, patients who contributed no data dur-
ing the efficacy assessment phase were considered to have
not achieved the primary efficacy end point (ie, nonre-
sponder imputation). Due to the difference in imputation
methods, the estimated 95% CIs were slightly different
between the noninferiority analysis and the superiority
analysis of the end point of a reduction in PTH concentra-
tions of more than 30%. Themean weekly number of days of
vomiting or nausea in the first 8 weeks was compared using
a generalized (Poisson) mixed-effects model. Since noninfe-
riority was demonstrated, the 3 key secondary end points
were tested sequentially in the order presented above to
control family-wise type 1 error rate. All statistical analyses
were conducted using SAS statistical software version 9.2 or
above (SAS Institute Inc).
Results
Enrollment
Sixhundredeighty-threepatientswereenrolled (340 random-
ized to receiveetelcalcetideand343 to receivecinacalcet) from
August2013toMay2014,withtheend-of-participant follow-up
in January 2015. The disposition of trial participants is shown
in Figure 1. The proportion of randomized patients by coun-
try is shown in eTable 1 in Supplement 9.
Baseline Characteristics
Table 1 shows selectedbaselinedemographic and clinical data
for patients by randomized treatment group; eTable 2 in
Supplement 9 shows additional detail. Baseline characteris-
ticsofpatients randomizedtoetelcalcetideandcinacalcetwere
generally well balanced.
Table 1. Baseline Patient Characteristics
Etelcalcetide
(n = 340)
Cinacalcet
(n = 343)
Age, mean (SD), y 54.0 (13.81) 55.3 (14.41)
Women, No. (%) 148 (43.5) 151 (44.0)
Race/ethnicity, No. (%)
White 261 (76.8) 277 (80.8)
Black (or African American) 54 (15.9) 52 (15.2)
Asian 9 (2.6) 7 (2.0)
Native Hawaiian or other Pacific Islander 6 (1.8) 3 (0.9)
American Indian or Alaskan Native 0 (0) 0 (0)
Other 10 (2.9) 4 (1.2)
Hispanic 38 (11.2) 41 (12.0)
Time since initiation of dialysis, median (IQR), y 4.4 (2.0-7.8) 4.1 (1.7-7.5)
Primary cause of ESRD, No. (%)
Diabetes mellitus 77 (22.6) 66 (19.2)
Hypertension 70 (20.6) 80 (23.3)
Glomerulonephritis 78 (22.9) 61 (17.8)
Polycystic kidney disease 27 (7.9) 36 (10.5)
Urologic 19 (5.6) 16 (4.7)
Other 46 (13.5) 52 (15.2)
Unknown 23 (6.8) 32 (9.3)
History, No. (%)
Kidney transplant 58 (17.1) 48 (14.0)
Cinacalcet use 80 (23.5) 92 (26.8)
Dialysis Modality, No. (%)
Hemodiafiltration 85 (25.0) 79 (23.0)
Hemodialysis 255 (75.0) 264 (77.0)
Dialysate calcium, ≥3.0 mEq/L, No. (%) 149 (43.8) 154 (44.9)
Parathyroid hormone, pg/mL
Median (IQR) 900 (685-1266) 930 (694-1327)
Mean (SD) 1092 (623) 1139 (707)
Calcium, albumin-corrected, mean (SD), mg/dL 9.67 (0.71) 9.58 (0.67)
Phosphate, mean (SD), mg/dL 5.81 (1.69) 5.82 (1.58)
FGF23, median (IQR), pg/mL 4033 (934-14 701) 2984 (877-12 160)
Bone-specific alkaline phosphatase, median (IQR), μg/L 29.3 (18.3-50.1) 30.0 (20.2-53.4)
Collagen type I cross-linked C-telopeptide, median (IQR), ng/L 3160 (2120-4600) 3310 (2290-4520)
Abbreviations: ESRD, end-stage renal
disease; FGF23, fibroblast growth
factor 23; IQR, interquartile range.
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Etelcalcetide and Cinacalcet Dosing
Themedian average weekly etelcalcetide dose during the ef-
ficacyassessmentphasewas15.0mg(interquartile range [IQR],
9.2-30.0mg)and themedianaveragedaily cinacalcetdosewas
51.4 mg (IQR, 26.4-80.4 mg).
Primary and Secondary Laboratory Determinations
Mean serum PTH, calcium, and phosphate concentrations
over time are shown in panels A through C and the percent
change in PTH concentrations is shown in panel D of
Figure 2. There were 42 patients (12.4%) in the group ran-
domized to etelcalcetide and 33 patients (9.6%) in the group
randomized to cinacalcet with no PTH data during the effi-
cacy assessment phase. With respect to the primary end
point (the proportion of patients achieving a reduction in
mean PTH concentrations of >30% from baseline during
weeks 20-27), the estimated difference between patients ran-
domized to cinacalcet was 57.7% (198 of 343) and to etelcal-
cetide was 68.2% (232 of 340) in proportions achieving the
end point was −10.5% (−17.5% to −3.5%; P for noninferiority,
<.001; P for superiority, .004). Because the upper bound of
the 95% CI was less than the prespecified noninferiority mar-
gin of 12%, the noninferiority criterion was met. One hun-
dred seventy-eight patients (52.4%) randomized to etelcal-
cetide achieved a reduction in PTH concentrations of more
than 50%, whereas 138 patients (40.2%) randomized to cina-
calcet achieved a reduction in PTH concentrations of more
than 50% (P = .001, difference in proportions, 12.2%; 95% CI,
4.7% to 19.5%) and for a reduction of more than 30%, the dif-
ference in proportions was 10.5% (95% CI, 3.3% to 17.7%).
The relative proportion of patients achieving a reduction in
PTH concentrations of more than 30% did not differ signifi-
cantly across any of the patient subgroups examined
(Figure 3).
Cointerventions
eFigure 1, panels A and B in Supplement 9 show increases in
the proportion of patients in both groups using calcium
Figure 2. Parathyroid Hormone, Calcium, and Phosphate Concentrations in Patients Receiving Cinacalcet or Etelcalcetide by StudyWeek
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supplements or calcium-containing phosphate binders and
calcitriol or active vitamin D analogs, respectively. eTable 4
in Supplement 9 shows the proportion of patients treated
with dialysate calcium concentrations of 2.5, more than 2.5
and less than 3.5, and 3.5 mEq/L at baseline and at the end of
the study. In both groups, the proportion of patients using
higher dialysate calcium concentrations was higher at the
end of the study relative to the baseline, indicating a cointer-
ventionmost likely prompted by relative reductions in serum
calcium induced by both calcimimetic agents.
FGF23 andMarkers of Bone Turnover
eFigure 2 in Supplement 9 shows the proportion of patients
achieving a reduction in FGF23 of more than 30% from
baseline to week 27 (panel A), the median percent change
from baseline in FGF23 to weeks 12 and 27 (panel B), and
the median percent change from baseline in bone-specific
alkaline phosphate and collagen type 1 cross-linked C to
weeks 12 and 27 (panel C). Etelcalcetide treatment yielded
more pronounced reductions in FGF23 and in both markers
of bone turnover.
Self-reported Nausea and Vomiting
The adjustedmean [SE]weekly days of vomiting or nausea in
the first 8weeks of treatmentwere not significantly different
for patients randomized to etelcalcetide (0.4 [0.04]) and cina-
calcet (0.3 [0.03]), corresponding to a rate ratio of 1.20 (95%
CI, 0.89-1.49).
Adverse Events
Of the 338 patients treated with etelcalcetide, 62 (18.3%)
reported nausea and 45 (13.3%), vomiting. Of the 341 patients
treated with cincalcet, 77 (22.6%) reported nausea and 47
(13.8%), vomiting. Death occurred in 9 patients (2.7%) in the
etelcalcetide-treated group and 6 (1.8%) in the cinacalcet-
treated group; corresponding figures for heart failure events
Figure 3. Forest Plot for Difference in ProportionWithMore Than 30%Decrease FromBaseline in Parathyroid Hormone Levels
–30 0 40–10 302010
Between-Group Difference in the
Proportion With >30% Decrease From
Baseline in PTH Level, % (95% CI)
–20
Favors
Cinacalcet
Favors
Etelcalcetide
No./Total of Patients
Etelcalcetide CinacalcetSubgroups
Screening, PTH level, pg/mL
Between-Group Difference
in Proportion With >30%
Decrease From Baseline
in PTH Level, % (95% CI)
121/167 97/154<900 9.5 (–0.7 to 19.7)
232/340 198/343Overall 10.5 (3.3 to 17.7)
110/171 97/182≥900 11.0 (0.8 to 21.2)
Race
38/54 28/52Black 16.5 (–1.7 to 34.7)
194/286 170/291White or other 9.4 (1.6 to 17.2)
Previous cinacalcet use
53/80 49/92Yes 13.0 (–1.5 to 27.5)
179/260 149/251No 9.5 (1.2 to 17.8)
Sex
125/192 106/192Men 9.9 (0.2 to 19.6)
107/148 92/151Women 11.4 (0.8 to 22.0)
Age, y
176/262 130/243<65 13.7 (5.2 to 22.1)
56/78 68/100≥65 3.8 (–9.7 to 17.3)
Region
67/103 54/105North America 13.6 (0.3 to 26.9)
165/237 144/238Non-North America 9.1 (0.6 to 17.7)
Time since initiation of dialysis, y
33/46 36/480-≤1 –3.3 (–21.1 to 14.6)
95/149 84/146>1-≤5 6.2 (–4.9 to 17.4)
104/145 78/149>5 19.4 (8.5 to 30.2)
Baseline
Dialysate calcium, mEq/L
128/191 104/189<3.0 12.0 (2.3 to 21.7)
104/149 94/154≥3.0 8.8 (–1.9 to 19.4)
Vitamin D sterol use
143/200 122/206Yes 12.3 (3.1 to 21.5)
89/140 76/137No 8.1 (–3.4 to 19.6)
Calcium-containing phosphate binder or calcium supplement use
119/172 101/168Yes 9.1 (–1.1 to 19.2)
113/168 97/175No 11.8 (1.6 to 22.1)
PTH indicates parathyroid hormone. To convert PTH from pg/mL to ng/L, multiply by 0.1053.
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were 10 (3.0%) and 2 (0.6%), respectively, of which 5 and 1
were considered serious. Decreased blood calcium developed
in 233 patients (68.9%) in the etelcalcetide-treated group and
204 patients (59.8%) in the cinacalcet-treated group. eFigure
3 in Supplement 9 shows time to first episode of albumin-
corrected serum calcium of less than 7.5 mg/dL. A full listing
of treatment emergent adverse events with a frequency of at
least 5% in either treatment group is shown in Table 2. A
more comprehensive listing of treatment emergent adverse
events is provided in eTable 3 in Supplement 9.
Discussion
In this double-blind, double-dummy randomized head-
to-head comparison of etelcalcetide and cinacalcet in
patients receiving hemodialysis with moderate to severe sec-
ondary hyperparathyroidism, PTH lowering was noninferior
with etelcalcetide, the primary end point of the trial. Second-
ary superiority end points were also reached; 52.4% of
patients randomized to etelcalcetide vs 40.2% of patients
randomized to cinacalcet experienced a 50% reduction in
PTH concentrations from baseline. Etelcalcetide also yielded
more potent reductions in serum concentrations of the phos-
phatonin FGF23 and 2 markers of high-turnover bone dis-
ease. There was no significant difference in self-reported
nausea and vomiting. Patients treated with etelcalcetide
were more likely to experience reduced serum calcium,
although there was similar use of interventions in both
groups to counter this effect.
Etelcalcetide is an octapeptide type 2 calcimimetic that
interacts with the calcium sensing receptor at a site distinct
from cinacalcet.8 Although the acute pharmacodynamic
effects of etelcalcetide are similar to those of cinacalcet, the
pharmacokinetic profile is distinct. Etelcalcetide is renally
cleared, with a half-life allowing thrice weekly administra-
tion (concurrent with hemodialysis), yielded sustained
reductions in PTH over the 48- to 72-hour dosing interval.9 It
is plausible that this pharmacokinetic difference contributes
to the superior efficacy demonstrated over 27 weeks in
reducing PTH, as well as the effects on serum calcium, phos-
phate, and FGF23 levels.
Data from the Dialysis Outcomes and Practice Pattern
Study (DOPPS) suggest that PTH concentrations have been
rising globally and that patients receiving dialysis with PTH
levels higher than 600 pg/mL experience an increased risk of
mortality.2 Among patients with inadequately controlled PTH
or phosphate concentrations, achieving reductions toward
target values is associated with improved survival.10,11
The primary analysis of the EVOLVE trial, an unadjusted
intention-to-treat comparison of cinacalcet vs placebo,
showed no significant difference.5 However, accounting for
baseline characteristics (mean age and the proportion of
older patients were higher in the cinacalcet group), there
were relative reductions in the primary composite end point
(12%), mortality (14%), and clinical fracture (17%).5,12
Poorly controlled secondary hyperparathyroidism re-
sults in reduced bone mass and may contribute to the exag-
gerated (and increasing) riskof fractureevident inpatientsun-
dergoing hemodialysis.13,14 The more profound effect of
etelcalcetide on biomarkers indicating high bone turnover
would be expected to yield favorable effects on bone remod-
eling and a reduction in fracture risk. The effect of etelcal-
cetide on FGF23 levels is also noteworthy. Fibroblast growth
factor 23 is profoundly elevated in patients with CKD15,16 and
has been causally linked to the development of left ventricu-
lar hypertrophy17 and heart failure.18 Treatment with cal-
citriol or active vitamin D analogs increases FGF23, whereas
treatmentwith cinacalcet reducesFGF23. In theEVOLVE trial,
a30%reduction inFGF23concentrations frombaselinetoweek
20wasassociatedwith significant reduction in risksof thepri-
mary composite endpoint, heart failure, and suddendeath.19
Reduced corrected serum calcium was common with
both treatments; however, it was more common with etelcal-
cetide than with cinacalcet. It is unclear if the occurrence of
levels of low serum calcium is entirely attributable to supe-
rior PTH lowering. While symptomatic hypocalcemia was
uncommon in both treatment groups, it should be empha-
sized that risks of adverse effects in clinical practice may
exceed those in carefully conducted randomized trials. A
sizeable fraction of patients taking etelcalcetide were pre-
scribed oral calcium, calcitriol, or vitamin D analogs and had
higher dialysate calcium concentrations. In the setting of
profound lowering of PTH concentrations in secondary
hyperparathyroidism, as occurs with parathyroidectomy,
there may be enhanced skeletal uptake of calcium and phos-
phate (“hungry bone”) resulting in remineralization and
improved bone structure and strength. However, it is unclear
Table 2. Treatment Emergent Adverse Eventsa
Preferred Term
Patients, No. (%)
Etelcalcetide
(n = 338)
Cinacalcet
(n = 341)
Blood calcium decreasedb 233 (68.9) 204 (59.8)
Nausea 62 (18.3) 77 (22.6)
Vomiting 45 (13.3) 47 (13.8)
Hypotension 23 (6.8) 10 (2.9)
Headache 22 (6.5) 24 (7.0)
Muscle spasms 22 (6.5) 20 (5.9)
Diarrhea 21 (6.2) 35 (10.3)
Hypertension 21 (6.2) 23 (6.7)
Anemia 17 (5.0) 15 (4.4)
Hypocalcemia 17 (5.0) 8 (2.3)
Pain in extremity 17 (5.0) 14 (4.1)
Bronchitis 5 (1.5) 17 (5.0)
a Adverse events occurring among 5% ormore patients in either group. The
term treatment emergent refers to a condition either not present before
exposure to a study drug that develops after drug exposure or a condition
present before exposure that worsens in frequency or severity. Adverse
events occurring after the first dose of study drug and up to 30 days after the
last dose of study drug were included. Counts and proportions refer to
patients rather than to adverse events. In other words, patients may have one
or more adverse event.
bDefined as an albumin-corrected serum calcium concentrations lower than 8.3
mg/dL (to convert to mmol/L, multiply by 0.25) that resulted in a medical
intervention.
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whether there are long-term adverse effects of inducing posi-
tive calcium balance in the setting of calcimimetic therapy.
Wehadanticipated thatetelcalcetidewould result in fewer
gastrointestinal symptoms than cinacalcet, in part due to the
IV route of administration. However, self-reported symp-
toms of nausea and vomiting were not significantly different
between the 2 randomized groups. In several placebo-
controlled trials, cinacalcet therapy resulted inhigher rates of
adverse gastrointestinal effects, principally nausea and
vomiting.3,20,21 In 2 large placebo-controlled trials of etelcal-
cetide, nausea was reported at rates 1.7-fold and vomiting at
rates 1.5-fold higher than those of placebo.3
Overall safety and tolerability were similar between
treatment groups. Although there were numerically more
episodes of heart failure in the etelcalcetide group, overall
event rates were similar to rates observed in the EVOLVE
trial. Initially, there were concerns that cinacalcet might
lead to heart failure and sudden death owing to the effects
of reduced serum calcium on myocardial contractility and
the QT interval, respectively. However, rates of heart failure
and sudden death were reduced in patients randomized to
cinacalcet in the EVOLVE trial.22
There are several important limitations to the trial.
Although trial participants reflected patients in practice
with moderate to severe secondary hyperparathyroidism
(ie, relatively young in age, with several years of dialysis
experience), we are unable to extrapolate efficacy and safety
data to older patients, patients new to dialysis, or both.
Although efficacy was sustained and relative safety demon-
strated over 26 weeks, secondary hyperparathyroidism is a
chronic condition often requiring life-long therapy; therefore,
longer-term safety data will be required. The trial’s major
limitation was its focus on lowering PTH levels, a surrogate
end point.
Conclusions
Among patients receiving hemodialysis with moderate to
severe secondary hyperparathyroidism, the use of etelcal-
cetide was not inferior to cinacalcet in reducing serum PTH
concentrations over 26 weeks; it also met superiority criteria.
Further studies are needed to assess clinical outcomes as well
as longer-term efficacy and safety.
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